See more : Maoye Commercial Co., Ltd. (600828.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Cortexyme, Inc. (CRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cortexyme, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NeuroSense Therapeutics Ltd. (NRSN) Income Statement Analysis – Financial Results
- Fujibo Holdings, Inc. (3104.T) Income Statement Analysis – Financial Results
- CuFe Ltd (CUF.AX) Income Statement Analysis – Financial Results
- Synopex Inc. (025320.KQ) Income Statement Analysis – Financial Results
- Igene Biotechnology, Inc. (IGNE) Income Statement Analysis – Financial Results
Cortexyme, Inc. (CRTX)
About Cortexyme, Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -90.32M | -78.89M | -39.17M | -11.47M | -10.55M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.95M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 373.00K | 2.04M | 2.19M | 600.00K | -222.00K |
| Net Income | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| EPS Diluted | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
Bristol Myers Squibb NDA, And Other News: The Good, Bad And Ugly Of Biopharma
Bristol Myers Squibb resubmits multiple myeloma therapy application. Onconova reports progress of INSPIRE trial data analysis.
Stocks To Watch: Big Focus On Big Tech
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020
Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed wit
Legal & General Group Plc Trims Position in Cortexyme, Inc. (NASDAQ:CRTX)
Legal & General Group Plc lessened its stake in Cortexyme, Inc. (NASDAQ:CRTX) by 22.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,809 shares of the biopharmaceutical company’s...
V&M Premium Portfolio: 2020 Mid-Year Report Card Through Week 26
The Premium Portfolio is up +14.43% YTD, while the benchmark S&P 500 Index is down -6.86% through June 26th. The Premium Portfolio has beaten the S&P 500 every
HC Wainwright Initiates Coverage on Cortexyme (NASDAQ:CRTX)
Analysts at HC Wainwright initiated coverage on shares of Cortexyme (NASDAQ:CRTX) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $76.00 price target on the biopharmaceutical company’s stock....
Cortexyme (NASDAQ:CRTX) Stock Rating Lowered by Zacks Investment Research
Cortexyme (NASDAQ:CRTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Cortexyme Inc. is a clinical-stage biopharmaceutical company. It...
Citigroup Inc. Has $158,000 Stock Holdings in Cortexyme, Inc. (NASDAQ:CRTX)
Citigroup Inc. increased its position in Cortexyme, Inc. (NASDAQ:CRTX) by 50.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,470 shares of the biopharmaceutical...
Insider Weekends: Director Of Accelerate Diagnostics Adds To His Stock
Insider buying decreased significantly last week. Notable Insider Buys: Accelerate Diagnostics, Inc., Keurig Dr Pepper Inc., Vishay Precision Group, Inc., Corte
David Lamond Acquires 49,125 Shares of Cortexyme, Inc. (NASDAQ:CRTX) Stock
Cortexyme, Inc. (NASDAQ:CRTX) Director David Lamond acquired 49,125 shares of Cortexyme stock in a transaction that occurred on Thursday, June 4th. The stock was acquired at an average cost of $41.73 per share, for a total transaction of $2,049,986.25. Following...
Source: https://incomestatements.info
Category: Stock Reports